Naturalendo Tech Co., Ltd. announced that it has received KRW 5 billion in funding from KDB Daewoo Securities Co. Ltd., Investment Arm, Samsung Securities Co. Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm
August 30, 2016
Share
Naturalendo Tech Co., Ltd. (KOSDAQ:A168330) announced a private placement of eighth unregistered/unsecured private convertible bonds for gross proceeds of KRW 5,000,000,000 on August 30, 2016. The transaction included participation from KDB Daewoo Securities Co. Ltd., Investment Arm, Samsung Securities Co. Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, and other investors. The conversion of bonds will start from August 31, 2017. The bond will be convertible at a fixed conversion price of KRW 17,800 per share with a yield to maturity of 3%.
Naturalendo Tech Co.,Ltd. is a Korea-based company principally engaged in the research and development (R&D) and manufacture of hormone biotechnology products. The Company mainly provides novel phytoestrogen, which is applied in the treatment of climacteric. It also provides other hormonal formula, such as hormone disruptor inhibitor, secretagogue and inhibitor used as diet formula and growth hormone. In addition, the Company provides materials used for diet, and involves in the R&D of drug delivery systems, immune enhancer, atopy and acne, plantation factory, and others.
Naturalendo Tech Co., Ltd. announced that it has received KRW 5 billion in funding from KDB Daewoo Securities Co. Ltd., Investment Arm, Samsung Securities Co. Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm
NATURALENDO TECH CO., LTD. 